Jonathan T. Lord, M.D.
A nationally recognized leader in innovations in health care, Jonathan "Jack" Lord, M.D, is actively engaged in driving change in healthcare through new technologies and therapies. Dr. Lord is a board-certified forensic pathologist and Fellow of the College of American Pathologists. He began his medical career in the U.S. Navy, serving for 11 years in a number of leadership roles in the Navy Medical Department. He later served as a senior executive in a variety of healthcare organizations - the Anne Arundel Medical Center, SunHealth and as the chief operating officer of the American Hospital Association. Lord was the former chief innovation officer and senior vice president of Humana - during his time at Humana, he created Humana's Innovation Center, which combined research, technology and consumer experience to promote health and well-being. He also contributed to the field of predictive sciences by using advanced analytics to predict who will become ill in the future and how to prevent disease. Recently he served as the Chief Innovation Officer and Chief Operating Officer of the Miller School of Medicine at the University of Miami; he is a double alumnus of the University of Miami.
Dr. Lord also serves or has served as a member of a number of prestigious boards and organizations, including the Centers for Disease Control and Prevention's Advisory Committee to the Director; the National Advisory Council for Healthcare Research and Quality, which advises the U.S. Secretary of Health and Human Services; and the editorial board for the International Journal of Healthcare Management. His previous academic appointments include Dartmouth Medical School, George Washington University and the Eastern Virginia School of Medicine
Dr. Lord focuses on the commercialization of disruptive innovations that change people lives; including companies that have done that - Health Dialog, Humana, Therasense, Stericycle, Mako Surgical and Dexcom. Today he serves as the Chair of the Board of Directors of Dexcom (DXCM), is a Director for Biolase (BIOL), Digital Reasoning, Par8o, Creative Vascular, Hubble Telemedical, and Vigilant Biosciences. He also serves on advisory board roles for Qualcomm Life (mobile health) and Third Rock Ventures. He has earned certificates in Governance and Audit from the Harvard Business School.
Michael DiTolla, DDS, FAGD
Dr. DiTolla is a seasoned dental executive and a graduate of the University of the Pacific School of Dentistry. Mike was awarded his Fellowship in the Academy of General Dentistry (FAGD) in 1995. He was in private practice for 15 years before becoming Director of Clinical Education for Glidewell Labs for the next 15 years, giving him an intimate knowledge of American dentists' crown and bridge habits. From 2006 to 2009, Mike led the clinical team that developed and brought BruxZir Solid Zirconia to market. In 2011, he received the "Most Effective Dentist Educator" award in a nationwide survey of dentists. In 2015, he became the Director of Clinical Affairs for Sirona, and, in 2017, he became the VP of Clinical Affairs for AEGIS Communications. He has given over 1,000 lectures to dentists worldwide, and his online videos have been viewed more than 15 million views by dentists worldwide.
Richard B. Lanman, M.D.
Richard B. Lanman, M.D. was appointed to the BIOLASE Board of Directors in November 2017. Dr Lanman is a well-known biotechnology entrepreneur who specializes in accelerating the development and adoption of novel medical technologies. He is a board-certified neurologist and physiatrist currently serving as the Chief Medical Officer at Guardant Health, Inc. During his career, he has served on a number of Boards of Directors and Advisory Boards and he has authored 45 articles that have been published in peer reviewed scientific journals. He has been appointed to serve on the Company's Audit, Compensation, and Nominating and Corporate Governance committees.
Dr. Lanman joined Guardant Health, Inc. in September 2014 and as its Chief Medical Officer, he has planned and executed the clinical and analytical validity, and clinical utility studies to bring novel cell-free DNA next generation sequencing technology to widespread adoption. From July 2008 until September 2014 Dr. Lanman was with Veracyte, Inc., where he drove the validation and clinical utility studies required to commercialize genomic diagnostics in thyroid and lung neoplasia that facilitate improved diagnosis utilizing small, minimally-invasive biopsies. Veracyte went public in 2013. He also previously served as Chief Medical Officer for two cardiovascular biodiagnostic companies, diaDexus and Atherotech, and prior to that, Dr. Lanman was the medical director and senior vice president of San Jose Medical Group and a Chief of Quality at Kaiser Permanente.
Todd A. Norbe
Todd Norbe was named President and CEO of BIOLASE, Inc. on August 8, 2018. Just prior to becoming CEO, Todd joined the BIOLASE Board of Directors in June 2018. Todd brings broad experience in the global dental industry, most recently as President, North America of KaVo Kerr, a subsidiary of the Danaher Corporation. KaVo Kerr delivers dental instruments, imaging solutions, dental treatment units and premier consumables worldwide. Previously, he served as Vice President and General Manager of Metrex Medical - Sybron Dental Specialties, continuing in that role after it was acquired by Danaher in 2006.
Todd has an MBA in Management from Fairleigh Dickinson University and a BS in Marketing from Bloomsburg University. He has also served on the Board of the Dental Trade Association Foundation and the National Children's Oral Health Foundation.
Jess Roper was appointed to the BIOLASE Board of Directors in June 2018 and serves as the Chairman of its Audit Committee. Mr. Roper has considerable financial and audit experience in the sectors of medical devices, life sciences, technology, manufacturing, and financial institutions. He joined San Diego-based Dexcom, Inc., in 2005 and he most recently served as its Senior Vice President and Chief Financial Officer, retiring in April 2017. Dexcom is a developer and marketer of continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital. During his tenure, Dexcom transitioned from a pre-revenue privately held medical device company to a multi-national, publicly traded entity with 2016 worldwide revenues of $573 million. Mr. Roper previously held financial management positions with two other publicly traded companies and one venture funded company and has extensive capital markets experience. Earlier in his career, Mr. Roper was an auditor with PricewaterhouseCoopers, and a bank and information systems examiner with the Office of the Comptroller of the Currency. Mr. Roper earned a Master of Science in Corporate Accountancy and a Bachelor of Science in Business Administration in Finance from San Diego State University. He is a Certified Public Accountant in California and a member of the Corporate Directors Forum.
Garrett Sato joins the BIOLASE Board with more than 30 years of experience as a successful consultant and senior executive with companies in the dental industry and has served as a senior advisor and executive partner with private equity and investment banking firms.
Most recently, from December 2013 to February 2016, he was Chairman and Chief Executive Officer of California-based Danville Materials LLC, a developer and manufacturer of dental clinic materials. As an industry executive operating partner with the private equity firm of Inverness Graham Investments, he led Denville through a period of revenue growth of approximately 35%, increased EBITDA by nearly 240%, improved operating margins and implemented a three-year strategic plan. Zest Dental Solutions, Inc., acquired Danville Materials in February 2016. Previously, from June 2011 through December 2013, Mr. Sato served as a consultant and advisor to several businesses, including New Zealand-based Triodent Corporation, where he served as Executive Director; Santa Barbara, CA-based Isolite Corporation; Kyoto, Japan-based Shofu Corporation; Canada-based Clinicians Research Dental Inc.; and Japan-based Mani Corporation. From October 2009 to June 2011, Mr. Sato was Executive Vice President of Culver City, CA-based Discus Dental, a Philips Company. At Discus Dental, Mr. Sato helped plan and executed a successful strategic turnaround that resulted in improved revenue and profit gains.
Mr. Sato has a Bachelor of Science degree in marketing from California State University, Long Beach.
Elaine C. Wagner, DDS
Dr. Wagner is the first female board-certified pediatric dentist to be promoted to the rank of Rear Admiral, upper-half, in the United States Navy Dental Corps. She completed residency at Riley Children's Hospital in Indianapolis in 1982 and was certified by the American Board of Pediatric Dentistry in 1991. After 18 months in private practice, Dr. Wagner was commissioned in the US Navy in 1983. After distinguished tours in San Diego and the Philippines, she was assigned to the National Naval Medical Center as the Dental Department's first pediatric dentist in 1992. Following that assignment, her career carried her through many distinguished Navy dental positions, including a year as a Commanding Officer at the Navy's Expeditionary Medical Facility (EMF) in Kuwait. In 2009, Dr. Wagner assumed command of the Naval Health Clinic New England. The following year, she assumed the duties as the director, Medical Resources Plans and Policy Division, Office of the Chief of Naval Operations code N931 and chief, Navy Dental Corps. From 2011 to 2014, she served as the commander of Navy Medicine East and Naval Medical Center Portsmouth, and as director of the Tidewater Enhanced Multi-Service Market. From 2014 until she retired in 2017, Dr. Wagner served at the Navy's Bureau of Medicine and Surgery in Falls Church, Virginia as the Director for Readiness and Health.
Dr. Wagner currently serves as the Registrar/Executive Director for the International College of Dentists USA Section. Her military decorations and awards include the Legion of Merit with three gold stars, Meritorious Service Medal with three gold stars, Navy and Marine Corps Commendation Medal with three gold stars, and the Navy and Marine Corps Achievement Medal with two gold stars.